TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare nerve disease? early trial tests patisiran
Disease control OngoingThis early-phase study tests the drug patisiran in 10 adults with a rare disease called wild-type ATTR amyloidosis that causes nerve damage. The goal is to see if patisiran can improve nerve function and quality of life over 24 months. Participants will have regular check-ups and…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Austin Neuromuscular Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New algorithm could spot hidden cases of rare amyloidosis
Diagnosis TerminatedThis study aimed to see if a computer algorithm could correctly identify patients with ATTR amyloidosis, a rare disease that affects the heart and nerves, by looking at insurance claims and medical records. The plan was to check how well the algorithm works and find people who mi…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: EARLY_PHASE1 • Sponsor: Yale University • Aim: Diagnosis
Last updated May 06, 2026 16:01 UTC
-
New study aims to catch a rare heart condition earlier in primary care
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing a way to find a rare heart condition called cardiac amyloidosis earlier in older adults. Researchers will screen 800 people aged 65 and older who have certain heart or muscle symptoms. The goal is to see if simple blood tests in family medicine clinics can h…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: Kotyora Family Medicine Health Management and Education Association • Aim: Knowledge-focused
Last updated May 17, 2026 10:27 UTC
-
Heart mystery: do Nerve-Targeting drugs also protect the heart?
Knowledge-focused OngoingThis study looks at 20 adults with hereditary transthyretin amyloidosis (a rare disease causing protein buildup in nerves and heart) who are already taking patisiran or vutrisiran for nerve symptoms. Researchers want to see if these drugs also affect heart structure and function …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated May 11, 2026 20:40 UTC